Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 190-193

  Jennens, R ^a   Rischin, D ^a   Yuen, K ^a   Toner, G ^a   Millward, M ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Crossover studies; Neutropenia; Ovarian neoplasms; Paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; METHODOLOGY; MYALGIA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

EID: 0141757447     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00459-1     Document Type: Article

References (9)

1. Eisenhauer E.A., ten Bokkel Huinink W.W., Swnerton K.D., Gianni L., Myles J., van der Burg M.E., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer high-dose versus low-dose and long versus short infusion . J Clin Oncol. 12:1994;2654-2666.
2. Smith R.E., Brown A.M., Mamounas E.P., Anderson S.J., Lembersky B.C., Atkins J.H., et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer National Surgical Adjuvant Breast and Bowel Project Protocol B-26 . J Clin Oncol. 17:1999;3403-3411.
3. Rischin D., Webster L.K., Millward M.J., Linahan B.M., Toner G.C., Woollett A.M., et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst. 88:1996;1297-1301.
4. Jones B., Kenwood M.G. Design and analysis of cross-over trials. 1989;Chapman & Hall, London.
5. SPSS Release 11.0.1. Chicago: SPSS Inc; 2001.
6. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Lacatelli A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 13:1995;180-190.
7. Huizing M.T., Keung A.C., Rosing H., van der Kuij V., ten Bokkel Huinink W.W., Mandjes I.M., et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 11:1993;2127-2135.
8. Karlsson M.O., Molnar V., Bergh J., Freijs A., Larrson M. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther. 63:1998;11-25.
9. Minami H., Sasaki Y., Saijo N., Ohtsu T., Fujii H., Igarashi T., Itoh K. Indirect-response model for the time course of leukopenia with anti-cancer drugs. Clin Pharmacol Ther. 64:1998;511-521.